bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 5 from Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
Authors: Moschetta Michele , Basile Antonio , Ferrucci Arianna , Frassanito Maria Antonia , Rao Luigia , Ria Roberto , Solimando Antonio Giovanni , Giuliani Nicola , Boccarelli Angelina , Fumarola Fabio , Coluccia Mauro , Rossini Bernardo , Ruggieri Simona , Nico Beatrice , Maiorano Eugenio , Ribatti Domenico , Roccaro Aldo M. , Vacca Angelo
Published: April 2023

PDF file, 113K, Effect of SU11274 treatment on PCs of newly diagnosed MM patients.
CCR Translation for This Article from Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
Authors: Kong Seogkyoung , Sengupta Sadhak , Tyler Betty , Bais Anthony J. , Ma Qiangzhong , Doucette Saryn , Zhou Jinyuan , Sahin Ayguen , Carter Bob S. , Brem Henry , Junghans Richard P. , Sampath Prakash
Published: April 2023

CCR Translation for This Article from Suppression of Human Glioma Xenografts with Second-Generation IL13R-Specific Chimeric Antigen Receptor–Modified T Cells
Supplementary Figure 2 from In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
Authors: Benzaïd Ismahène , Mönkkönen Hannu , Bonnelye Edith , Mönkkönen Jukka , Clézardin Philippe
Published: April 2023

PDF file - 173K, IPP/ApppI phosphoantigen accumulation induced by RIS and cellular uptake of RIS in breast cancer cell lines
Supplementary Table 2 from Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
Authors: Lionetti Marta , Musto Pellegrino , Di Martino Maria Teresa , Fabris Sonia , Agnelli Luca , Todoerti Katia , Tuana Giacomo , Mosca Laura , Gallo Cantafio Maria E. , Grieco Vitina , Bianchino Gabriella , D'Auria Fiorella , Statuto Teodora , Mazzoccoli Carmela , De Luca Luciana , Petrucci Maria Teresa , Offidani Massimo , Di Raimondo Francesco , Falcone Antonietta , Caravita Tommaso , Omede' Paola , Morabito Fortunato , Tassone Pierfrancesco , Boccadoro Mario , Palumbo Antonio , Neri Antonino
Published: April 2023

PDF file - 39K, Anticorrelation results and functional annotations analysis of differentially expressed miRNAs between pPCL and MM patients.
Supplementary Figure 3 from Circulating miRNAs as Surrogate Markers for Circulating Tumor Cells and Prognostic Markers in Metastatic Breast Cancer
Authors: Madhavan Dharanija , Zucknick Manuela , Wallwiener Markus , Cuk Katarina , Modugno Caroline , Scharpff Martina , Schott Sarah , Heil Jörg , Turchinovich Andrey , Yang Rongxi , Benner Axel , Riethdorf Sabine , Trumpp Andreas , Sohn Christof , Pantel Klaus , Schneeweiss Andreas , Burwinkel Barbara
Published: April 2023

PDF file, 99K, Prediction error curves for miRNA models.
Supplementary Figure Legend from Carfilzomib and ONX 0912 Inhibit Cell Survival and Tumor Growth of Head and Neck Cancer and Their Activities Are Enhanced by Suppression of Mcl-1 or Autophagy
Authors: Zang Yan , Thomas Sufi M. , Chan Elena T. , Kirk Christopher J. , Freilino Maria L. , DeLancey Hannah M. , Grandis Jennifer R. , Li Changyou , Johnson Daniel E.
Published: April 2023

PDF file, 64K.
Supplementary Figure 3 from A Functional Variant at 19q13.3, rs967591G>A, Is Associated with Shorter Survival of Early-Stage Lung Cancer
Authors: Jeon Hyo-Sung , Jin Guang , Kang Hyo-Gyoung , Choi Yi Young , Lee Won Kee , Choi Jin Eun , Bae Eun Young , Yoo Seung Soo , Lee Shin Yup , Lee Eung Bae , Kim Young Tae , Lee Jaehee , Cha Seung-Ick , Kim Chang Ho , Jheon Sanghoon , Kim In San , Park Jae Yong
Published: April 2023

PDF file - 27K, The correlation between the CD3EAP gene copy number and mRNA expression. * Pearson correlation coefficient
Supplementary Figure 4 from The Effects of Chemotherapy on Cognitive Function in a Mouse Model: A Prospective Study
Authors: Winocur Gordon , Henkelman Mark , Wojtowicz J. Martin , Zhang Haibo , Binns Malcolm A. , Tannock Ian F.
Published: April 2023

PDF file, 31KB, Figure S4. Performance of CHEMO and SAL groups on the NMTS test administered at baseline. Errors represent the mean number of errors /trial/day in finding the submerged platform on the test trials over 10 days of testing. (Error bars denote � SEM)
Supplementary Table 2 from Increased miR-708 Expression in NSCLC and Its Association with Poor Survival in Lung Adenocarcinoma from Never Smokers
Authors: Jang Jin Sung , Jeon Hyo-Sung , Sun Zhifu , Aubry Marie Christine , Tang Hui , Park Cheol-Hong , Rakhshan Fariborz , Schultz Debra A. , Kolbert Christopher P. , Lupu Ruth , Park Jae Yong , Harris Curtis C. , Yang Ping , Jen Jin
Published: April 2023

PDF file, 87KB, Differentially Expressed Genes by miR-708 Status in Never-Smoker Lung Adenocarcinoma.
Supplementary Figure 4 from Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
Authors: Diamond Jennifer R. , Eckhardt S. Gail , Tan Aik Choon , Newton Timothy P. , Selby Heather M. , Brunkow Kelsey L. , Kachaeva Maria I. , Varella-Garcia Marileila , Pitts Todd M. , Bray Mark R. , Fletcher Graham C. , Tentler John J.
Published: April 2023

PDF file - 224K, Gene Set Enrichment Analysis (GSEA) of ENMD-2076 sensitivity including all breast cancer subtypes
Supplementary Figure 1 from Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models
Authors: Diamond Jennifer R. , Eckhardt S. Gail , Tan Aik Choon , Newton Timothy P. , Selby Heather M. , Brunkow Kelsey L. , Kachaeva Maria I. , Varella-Garcia Marileila , Pitts Todd M. , Bray Mark R. , Fletcher Graham C. , Tentler John J.
Published: April 2023

PDF file - 79K, FISH for AURKA
Supplementary Table 2 from Predicting Drug Responsiveness in Human Cancers Using Genetically Engineered Mice
Authors: Usary Jerry , Zhao Wei , Darr David , Roberts Patrick J. , Liu Mei , Balletta Lorraine , Karginova Olga , Jordan Jamie , Combest Austin , Bridges Arlene , Prat Aleix , Cheang Maggie C. U. , Herschkowitz Jason I. , Rosen Jeffrey M. , Zamboni William , Sharpless Norman E. , Perou Charles M.
Published: April 2023

XLSX file - 60K, Gene lists obtained from a study of carboplatin/paclitaxel treated tumors.
Supplementary Figure 3 from Novel Tumor Subgroups of Urothelial Carcinoma of the Bladder Defined by Integrated Genomic Analysis
Authors: Hurst Carolyn D. , Platt Fiona M. , Taylor Claire F. , Knowles Margaret A.
Published: April 2023

PDF file, 507K, Relationship between PTEN loss, RB1 loss and TP53 mutation status and time to metastasis.
Related Article from Hidden Dangers: A Cryptic Exon Disrupts BRCA2 mRNA
Authors: Fackenthal James D. , Lee Younghee , Olopade Olufunmilayo I.
Published: April 2023

Related Article from Hidden Dangers: A Cryptic Exon Disrupts BRCA2 mRNA
Supplementary Figure 3 from Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
Authors: Terashima Masanori , Kitada Koji , Ochiai Atsushi , Ichikawa Wataru , Kurahashi Issei , Sakuramoto Shinichi , Katai Hitoshi , Sano Takeshi , Imamura Hiroshi , Sasako Mitsuru
Published: April 2023

PDF file - 79K, Relationship between IHC scores and EGFR and HER2 messenger RNA (mRNA) levels
Supplementary Figure S1 from Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma
Authors: Nadal Ernest , Chen Guoan , Gallegos Marc , Lin Lin , Ferrer-Torres Daysha , Truini Anna , Wang Zhuwen , Lin Jules , Reddy Rishindra M. , Llatjos Roger , Escobar Ignacio , Moya Juan , Chang Andrew C. , Cardenal Felipe , Capellà Gabriel , Beer David G.
Published: April 2023

PDF file 193K, Analytical sensitivity of Melting Curve Analysis for assessing miR-34b/c methylation
Supplementary Figure 1 from Impact of Expression of Human Epidermal Growth Factor Receptors EGFR and ERBB2 on Survival in Stage II/III Gastric Cancer
Authors: Terashima Masanori , Kitada Koji , Ochiai Atsushi , Ichikawa Wataru , Kurahashi Issei , Sakuramoto Shinichi , Katai Hitoshi , Sano Takeshi , Imamura Hiroshi , Sasako Mitsuru
Published: April 2023

PDF file - 377K, Representative example of gastric carcinoma immunostaining for EGFR (magnification � 100)
Supplementary Figure 4 from Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays
Authors: Manfredi Mark G. , Ecsedy Jeffrey A. , Chakravarty Arijit , Silverman Lee , Zhang Mengkun , Hoar Kara M. , Stroud Stephen G. , Chen Wei , Shinde Vaishali , Huck Jessica J. , Wysong Deborah R. , Janowick David A. , Hyer Marc L. , LeRoy Patrick J. , Gershman Rachel E. , Silva Matthew D. , Germanos Melissa S. , Bolen Joseph B. , Claiborne Christopher F. , Sells Todd B.
Published: April 2023

PDF file - 34K
Supplementary Figure 2 from Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast Cancer
Authors: Zhang Liling , Riethdorf Sabine , Wu Gang , Wang Tao , Yang Kunyu , Peng Gang , Liu Junli , Pantel Klaus
Published: April 2023

PDF file, 847K, One-way sensitivity analyses.
Supplementary Table 1 from Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
Authors: Sangai Takafumi , Akcakanat Argun , Chen Huiqin , Tarco Emily , Wu Yun , Do Kim-Anh , Miller Todd W. , Arteaga Carlos L. , Mills Gordon B. , Gonzalez-Angulo Ana Maria , Meric-Bernstam Funda
Published: April 2023

PDF file, 60K, MK-2206 treatment and protein response.
Supplementary Table 1 from Brachyury, a Driver of the Epithelial–Mesenchymal Transition, Is Overexpressed in Human Lung Tumors: An Opportunity for Novel Interventions against Lung Cancer
Authors: Roselli Mario , Fernando Romaine I. , Guadagni Fiorella , Spila Antonella , Alessandroni Jhessica , Palmirotta Raffaele , Costarelli Leopoldo , Litzinger Mary , Hamilton Duane , Huang Bruce , Tucker Joanne , Tsang Kwong-Yok , Schlom Jeffrey , Palena Claudia
Published: April 2023

PDF file, 62KB, Analysis of Brachyury gene copy number and promoter methylation status.
Supplementary Table 2 from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Authors: Spreafico Anna , Tentler John J. , Pitts Todd M. , Tan Aik Choon , Gregory Mark A. , Arcaroli John J. , Klauck Peter J. , McManus Martine C. , Hansen Ryan J. , Kim Jihye , Micel Lindsey N. , Selby Heather M. , Newton Timothy P. , McPhillips Kelly L. , Gustafson Daniel L. , DeGregori James V. , Messersmith Wells A. , Winn Robert A. , Eckhardt S. Gail
Published: April 2023

Supplementary Table 2 - PDF file 62K, Suppl Table 2 IC50s for single agents and combination
Supplementary Table 2 from Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response
Authors: Wong Harvey , Choo Edna F. , Alicke Bruno , Ding Xiao , La Hank , McNamara Erin , Theil Frank-Peter , Tibbitts Jay , Friedman Lori S. , Hop Cornelis E.C.A. , Gould Stephen E.
Published: April 2023

PDF file - 70K, Listing of References for Clinical Response and Human Pharmacokinetics
Supplementary Methods from Rational Combination of a MEK Inhibitor, Selumetinib, and the Wnt/Calcium Pathway Modulator, Cyclosporin A, in Preclinical Models of Colorectal Cancer
Authors: Spreafico Anna , Tentler John J. , Pitts Todd M. , Tan Aik Choon , Gregory Mark A. , Arcaroli John J. , Klauck Peter J. , McManus Martine C. , Hansen Ryan J. , Kim Jihye , Micel Lindsey N. , Selby Heather M. , Newton Timothy P. , McPhillips Kelly L. , Gustafson Daniel L. , DeGregori James V. , Messersmith Wells A. , Winn Robert A. , Eckhardt S. Gail
Published: April 2023

Supplementary Methods - PDF file 124K, Supplementary Methods
Supplementary Figure 2 from Defective Epidermal Innate Immunity and Resultant Superficial Dermatophytosis in Adult T-cell Leukemia/Lymphoma
Authors: Sawada Yu , Nakamura Motonobu , Kabashima-Kubo Rieko , Shimauchi Takatoshi , Kobayashi Miwa , Tokura Yoshiki
Published: April 2023

PDF file, 2046KB, IL-17+ cells and CD25+ cells in skin lesions.
Supplementary Table 1 from HAb18G/CD147 Promotes pSTAT3-Mediated Pancreatic Cancer Development via CD44s
Authors: Li Ling , Tang Wenhua , Wu Xiaoqing , Karnak David , Meng Xiaojie , Thompson Rachel , Hao Xinbao , Li Yongmin , Qiao Xiaotan T. , Lin Jiayuh , Fuchs James , Simeone Diane M. , Chen Zhi-Nan , Lawrence Theodore S. , Xu Liang
Published: April 2023

PDF file - 112K, The sequences of the oligonucleotide primers used for qPCR (related to the qRT-PCR section of Materials and Methods).
Supplementary Table 1 from Temozolomide-Mediated DNA Methylation in Human Myeloid Precursor Cells: Differential Involvement of Intrinsic and Extrinsic Apoptotic Pathways
Authors: Wang Haiyan , Cai Shanbao , Ernstberger Aaron , Bailey Barbara J. , Wang Michael Z. , Cai Wenjing , Goebel W. Scott , Czader Magdalena B. , Crean Colin , Suvannasankha Attaya , Shokolenkoc Inna , Wilson Glenn L. , Baluyut Arthur R. , Mayo Lindsey D. , Pollok Karen E.
Published: April 2023

PDF file - 38K, This provides a supplemental table of gene expression data and background on the data set. The GEO accesssion number and hyperlink are included.
Supplementary Table 2 from Molecular Profiling Reveals Low- and High-Grade Forms of Primary Melanoma
Authors: Harbst Katja , Staaf Johan , Lauss Martin , Karlsson Anna , Måsbäck Anna , Johansson Iva , Bendahl Pär-Ola , Vallon-Christersson Johan , Törngren Therese , Ekedahl Henrik , Geisler Jürgen , Höglund Mattias , Ringnér Markus , Lundgren Lotta , Jirström Karin , Olsson Håkan , Ingvar Christian , Borg Åke , Tsao Hensin , Jönsson Göran
Published: April 2023

PDF file - 79K, Significant canonical pathways (p<0.05) identified in the Ingenuity analysis
Supplementary Table 3 from Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
Authors: Besser Michal J. , Shapira-Frommer Ronnie , Itzhaki Orit , Treves Avraham J. , Zippel Douglas B. , Levy Daphna , Kubi Adva , Shoshani Noa , Zikich Dragoslav , Ohayon Yaara , Ohayon Daniel , Shalmon Bruria , Markel Gal , Yerushalmi Ronit , Apter Sara , Ben-Nun Alon , Ben-Ami Eytan , Shimoni Avichai , Nagler Arnon , Schachter Jacob
Published: April 2023

PDF file - 60K, the baseline characteristics and response to ipilimumab in 19 patients previously treated with TIL ACT.
Supplementary Figure 3 from EGFR Protein Expression in Non–Small Cell Lung Cancer Predicts Response to an EGFR Tyrosine Kinase Inhibitor—A Novel Antibody for Immunohistochemistry or AQUA Technology
Authors: Mascaux Celine , Wynes Murry W. , Kato Yasufumi , Tran Cindy , Asuncion Bernadette Reyna , Zhao Jason M. , Gustavson Mark , Ranger-Moore Jim , Gaire Fabien , Matsubayashi Jun , Nagao Toshitaka , Yoshida Koichi , Ohira Tatuso , Ikeda Norihiko , Hirsch Fred R.
Published: April 2023

PDF file - 163KB
Related Article from Personalized Medicine: Through the Looking Glass of Functional Imaging
Authors: Hohl Raymond J.
Published: April 2023

Related Article from Personalized Medicine: Through the Looking Glass of Functional Imaging
Supplementary Figure 3 from Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features
Authors: Gammaitoni Loretta , Giraudo Lidia , Leuci Valeria , Todorovic Maja , Mesiano Giulia , Picciotto Franco , Pisacane Alberto , Zaccagna Alessandro , Volpe Maria Giuseppa , Gallo Susanna , Caravelli Daniela , Giacone Elena , Venesio Tiziana , Balsamo Antonella , Pignochino Ymera , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

PDF file - 193K, Representative flow cytometry analysis of a CIK cell culture generated from PBMC from mMel patients.
Supplementary Figure 2 from Effective Activity of Cytokine-Induced Killer Cells against Autologous Metastatic Melanoma Including Cells with Stemness Features
Authors: Gammaitoni Loretta , Giraudo Lidia , Leuci Valeria , Todorovic Maja , Mesiano Giulia , Picciotto Franco , Pisacane Alberto , Zaccagna Alessandro , Volpe Maria Giuseppa , Gallo Susanna , Caravelli Daniela , Giacone Elena , Venesio Tiziana , Balsamo Antonella , Pignochino Ymera , Grignani Giovanni , Carnevale-Schianca Fabrizio , Aglietta Massimo , Sangiolo Dario
Published: April 2023

PDF file - 147K, Representative flow cytometry analysis of melanoma primary cell cultures. assessment of CD117 (aka c-kit) and MCSP; c) assessment of MIC A/B and ULBP2; d) assessment of ULBP1 and ULBP3 expression; e) expression assessment of CD34 and VEGFR1 expression; f) assessment of intracellular Oct4 expression in fixed and permeabilized cells; g) assessment of ABCG2 expression; h) assessment of ALDH activity in cells stained with FITC ALDH substrate; i) assessment of MITF negativity in fixed and permeabilized cells stained with a primary specific antibody unconjugated and a PE conjugated secondary antibody; k) assessment of CD117 (also known as c-kit) and MCSP in mMel6, notably highly positive for CD117 expression.
Supplementary Methods and Figure Legend from Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
Authors: Ryan Charles J. , Rosenthal Mark , Ng Siobhan , Alumkal Joshi , Picus Joel , Gravis Gwenaëlle , Fizazi Karim , Forget Frédéric , Machiels Jean-Pascal , Srinivas Sandy , Zhu Min , Tang Rui , Oliner Kelly S. , Jiang Yizhou , Loh Elwyn , Dubey Sarita , Gerritsen Winald R.
Published: April 2023

PDF file - 63K
Supplementary Table S1 from Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor
Authors: Álvarez-Fernández Stela , Ortiz-Ruiz María Jesús , Parrott Tracy , Zaknoen Sara , Ocio Enrique M. , San Miguel Jesús , Burrows Francis J. , Esparís-Ogando Azucena , Pandiella Atanasio
Published: April 2023

Kinases inhibited by TG02 in the low nM range.
Supplementary Materials and Methods from PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
Authors: Meric-Bernstam Funda , Akcakanat Argun , Chen Huiqin , Do Kim-Anh , Sangai Takafumi , Adkins Farrell , Gonzalez-Angulo Ana Maria , Rashid Asif , Crosby Katherine , Dong Mei , Phan Alexandria T. , Wolff Robert A. , Gupta Sanjay , Mills Gordon B. , Yao James
Published: April 2023

PDF file - 103K
CCR Translation for This Article from Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups
Authors: Schroen Anneke T. , Petroni Gina R. , Wang Hongkun , Thielen Monika J. , Gray Robert , Benedetti Jacqueline , Wang Xiaofei F. , Sargent Daniel J. , Wickerham Donald L. , Cronin Walter , Djulbegovic Benjamin , Slingluff Craig L.
Published: April 2023

CCR Translation for This Article from Achieving Sufficient Accrual to Address the Primary Endpoint in Phase III Clinical Trials from U.S. Cooperative Oncology Groups
Supplementary Table 1 from Molecular Pathways: Tumor Cells Co-opt the Brain-Specific Metabolism Gene CPT1C to Promote Survival
Authors: Reilly Patrick T. , Mak Tak W.
Published: April 2023

PDF file - 110K, Table with clinico-biological data of the patients
Supplementary Figure 2 from NKX3.1 Haploinsufficiency Is Prognostic for Prostate Cancer Relapse following Surgery or Image-Guided Radiotherapy
Authors: Locke Jennifer A. , Zafarana Gaetano , Ishkanian Adrian S. , Milosevic Michael , Thoms John , Have Cherry L. , Malloff Chad A. , Lam Wan L. , Squire Jeremy A. , Pintilie Melania , Sykes Jenna , Ramnarine Varune Rohan , Meng Alice , Ahmed Omer , Jurisica Igor , van der Kwast Theo , Bristow Robert G.
Published: April 2023

PDF file - 41K, Percentage genome alteration (PGA) levels are displayed for patient biopsies categorized as per their NKX3.1/T-category status (a), NKX3.1/PSA status (b), NKX3.1/Gleason-score status (c), NKX3.1/c-MYC/T-category status (d) and NKX3.1/c-MYC/PSA status (e). The median PGA for each group is represented by the black line. (GS=Gleason-score, *=significantly different). Patients with NKX3.1 allelic loss have a significant increase in PGA as compared to patients with a normal status of NKX3.1 in T-category groups pT1=0.00045 and pT2<0.0001 (a). Patients with NKX3.1 allelic loss have a significant increase in PGA as compared to patients with a normal status of NKX3.1 in PSA p<=10<0.0001 and p>10=0.0012 (b). Patients with NKX3.1 allelic loss have a significant increase in PGA as compared to patients with a normal status of NKX3.1 in Gleason-scores pGS6=0.0015 and pGS7<0.0001 (c). Patients with NKX3.1 allelic loss and c-MYC allelic gain have a significant increase in PGA as compared to patients with a normal status of NKX3.1 and c-MYC in T-category groups pT1=0.00029 and pT2<0.0001 (d). Patients with NKX3.1 allelic loss and c-MYC allelic gain have a significant increase in PGA as compared to patients with a normal status of NKX3.1 and c-MYC in PSA p<=10<0.0001 and p>10=0.001 (e).
Supplementary Table 1 from Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier
Authors: Salphati Laurent , Heffron Timothy P. , Alicke Bruno , Nishimura Merry , Barck Kai , Carano Richard A. , Cheong Jonathan , Edgar Kyle A. , Greve Joan , Kharbanda Samir , Koeppen Hartmut , Lau Shari , Lee Leslie B. , Pang Jodie , Plise Emile G. , Pokorny Jenny L. , Reslan Hani Bou , Sarkaria Jann N. , Wallin Jeffrey J. , Zhang Xiaolin , Gould Stephen E. , Olivero Alan G. , Phillips Heidi S.
Published: April 2023

PDF file - 58K, Bioluminescence Analysis of U87 Intracranial Tumors in Mice at the Start of Treatment (Day 7 post-surgery) and at the End of Study (Day 28)
Supplementary Figure Legend from Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier
Authors: Salphati Laurent , Heffron Timothy P. , Alicke Bruno , Nishimura Merry , Barck Kai , Carano Richard A. , Cheong Jonathan , Edgar Kyle A. , Greve Joan , Kharbanda Samir , Koeppen Hartmut , Lau Shari , Lee Leslie B. , Pang Jodie , Plise Emile G. , Pokorny Jenny L. , Reslan Hani Bou , Sarkaria Jann N. , Wallin Jeffrey J. , Zhang Xiaolin , Gould Stephen E. , Olivero Alan G. , Phillips Heidi S.
Published: April 2023

PDF file - 55K
Supplementary Figure 2 from Targeting the PI3K Pathway in the Brain—Efficacy of a PI3K Inhibitor Optimized to Cross the Blood–Brain Barrier
Authors: Salphati Laurent , Heffron Timothy P. , Alicke Bruno , Nishimura Merry , Barck Kai , Carano Richard A. , Cheong Jonathan , Edgar Kyle A. , Greve Joan , Kharbanda Samir , Koeppen Hartmut , Lau Shari , Lee Leslie B. , Pang Jodie , Plise Emile G. , Pokorny Jenny L. , Reslan Hani Bou , Sarkaria Jann N. , Wallin Jeffrey J. , Zhang Xiaolin , Gould Stephen E. , Olivero Alan G. , Phillips Heidi S.
Published: April 2023

PDF file - 77K, Cell viability following treatment with GNE-317
Supplementary Figure 2 from Genome-Wide Somatic Copy Number Alterations in Low-Grade PanINs and IPMNs from Individuals with a Family History of Pancreatic Cancer
Authors: Hong Seung-Mo , Vincent Audrey , Kanda Mitsuro , Leclerc Julie , Omura Noriyuki , Borges Michael , Klein Alison P. , Canto Marcia Irene , Hruban Ralph H. , Goggins Michael
Published: April 2023

PDF file, 207KB, Supplemental Figure 2. High resolution melt-curve analysis (left panels) and pyrosequencing (right panels) data. A-B) mutant KRAS (G12V) from case 308 (PanIN-1 lesion). C-D) mutant KRAS (G12D) case 804 (PanIN-1 lesion). E-F) Wild type KRAS from cases 506 (IPMN with low-grade dysplasia). G-H) Wild-type KRAS control, SKMB cell line.
Related Article from Real-time Pathology to Guide Breast Surgery: Seeing Alone Is Not Believing
Authors: Bigio Irving J.
Published: April 2023

Related Article from Real-time Pathology to Guide Breast Surgery: Seeing Alone Is Not Believing
Supplementary Figure 1 from Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas
Authors: Griewank Klaus G. , Westekemper Henrike , Murali Rajmohan , Mach Monika , Schilling Bastian , Wiesner Thomas , Schimming Tobias , Livingstone Elisabeth , Sucker Antje , Grabellus Florian , Metz Claudia , Süsskind Daniela , Hillen Uwe , Speicher Michael R. , Woodman Scott E. , Steuhl Klaus-Peter , Schadendorf Dirk
Published: April 2023

PDF file - 65K, Supplemental Figure 1. Anatomical scheme of the eye.
Supplementary Figure 1-5 from Chondrolectin Is a Novel Diagnostic Biomarker and a Therapeutic Target for Lung Cancer
Authors: Masuda Ken , Takano Atsushi , Oshita Hideto , Akiyama Hirohiko , Tsuchiya Eiju , Kohno Nobuoki , Nakamura Yusuke , Daigo Yataro
Published: April 2023

PDF file - 272K
Supplementary Table 3 from ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Authors: Biddlestone-Thorpe Laura , Sajjad Muhammad , Rosenberg Elizabeth , Beckta Jason M. , Valerie Nicholas C.K. , Tokarz Mary , Adams Bret R. , Wagner Alison F. , Khalil Ashraf , Gilfor Donna , Golding Sarah E. , Deb Sumitra , Temesi David G. , Lau Alan , O'Connor Mark J. , Choe Kevin S. , Parada Luis F. , Lim Sang Kyun , Mukhopadhyay Nitai D. , Valerie Kristoffer
Published: April 2023

PDF file - 45K, Preparation of calibration and QC solutions.
Supplementary Table 1 from ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Authors: Biddlestone-Thorpe Laura , Sajjad Muhammad , Rosenberg Elizabeth , Beckta Jason M. , Valerie Nicholas C.K. , Tokarz Mary , Adams Bret R. , Wagner Alison F. , Khalil Ashraf , Gilfor Donna , Golding Sarah E. , Deb Sumitra , Temesi David G. , Lau Alan , O'Connor Mark J. , Choe Kevin S. , Parada Luis F. , Lim Sang Kyun , Mukhopadhyay Nitai D. , Valerie Kristoffer
Published: April 2023

PDF file - 58K, Concentrations of KU-60019 in mouse brain after CED.
Supplementary Figure 7 from ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
Authors: Biddlestone-Thorpe Laura , Sajjad Muhammad , Rosenberg Elizabeth , Beckta Jason M. , Valerie Nicholas C.K. , Tokarz Mary , Adams Bret R. , Wagner Alison F. , Khalil Ashraf , Gilfor Donna , Golding Sarah E. , Deb Sumitra , Temesi David G. , Lau Alan , O'Connor Mark J. , Choe Kevin S. , Parada Luis F. , Lim Sang Kyun , Mukhopadhyay Nitai D. , Valerie Kristoffer
Published: April 2023

PDF file - 80K, Imaging of U87/luc-DsRed (p53-281G) bearing mice.
Supplementary Figure 5 from PI3K/AKT Signaling Is Essential for Communication between Tissue-Infiltrating Mast Cells, Macrophages, and Epithelial Cells in Colitis-Induced Cancer
Authors: Khan Mohammad W. , Keshavarzian Ali , Gounaris Elias , Melson Joshua E. , Cheon Eric C. , Blatner Nichole R. , Chen Zongmin E. , Tsai Fu-Nien , Lee Goo , Ryu Hyunji , Barrett Terrence A. , Bentrem David J. , Beckhove Philipp , Khazaie Khashayarsha
Published: April 2023

PDF file - 97K, Multiplex ELISA data for human inflammatory chemoattractants.
Supplementary Figure 1 from Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas
Authors: Wakimoto Hiroaki , Tanaka Shota , Curry William T. , Loebel Franziska , Zhao Dan , Tateishi Kensuke , Chen Juxiang , Klofas Lindsay K. , Lelic Nina , Kim James C. , Dias-Santagata Dora , Ellisen Leif W. , Borger Darrell R. , Fendt Sarah-Maria , Vander Heiden Matthew G. , Batchelor Tracy T. , Iafrate A. John , Cahill Daniel P. , Chi Andrew S.
Published: April 2023

PDF file - 791KB, Supplementary Figure S1. Additional mouse orthotopic xenografts generated from patient IDH1 R132H-mutant gliomas.
Supplementary Table 2 from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis
Authors: Touil Yasmine , Igoudjil Wassila , Corvaisier Matthieu , Dessein Anne-Frédérique , Vandomme Jérôme , Monté Didier , Stechly Laurence , Skrypek Nicolas , Langlois Carole , Grard Georges , Millet Guillaume , Leteurtre Emmanuelle , Dumont Patrick , Truant Stéphanie , Pruvot François-René , Hebbar Mohamed , Fan Fan , Ellis Lee M. , Formstecher Pierre , Van Seuningen Isabelle , Gespach Christian , Polakowska Renata , Huet Guillemette
Published: April 2023

PDF file - 54K, Table S2. Effect of 5FU on the cell cycle progression in parental HT29 cells and 5FUresistant HT29 clonal derivatives 5F7 and 5F31.
Supplementary Figure 2 from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis
Authors: Touil Yasmine , Igoudjil Wassila , Corvaisier Matthieu , Dessein Anne-Frédérique , Vandomme Jérôme , Monté Didier , Stechly Laurence , Skrypek Nicolas , Langlois Carole , Grard Georges , Millet Guillaume , Leteurtre Emmanuelle , Dumont Patrick , Truant Stéphanie , Pruvot François-René , Hebbar Mohamed , Fan Fan , Ellis Lee M. , Formstecher Pierre , Van Seuningen Isabelle , Gespach Christian , Polakowska Renata , Huet Guillemette
Published: April 2023

PDF file - 202K, Figure S2. Western blot analysis of c-Yes and YAP in human colon cancer cells HT29 and RKO cells treated by oxaliplatin and 5FU.
Supplementary Figure 1 from Colon Cancer Cells Escape 5FU Chemotherapy-Induced Cell Death by Entering Stemness and Quiescence Associated with the c-Yes/YAP Axis
Authors: Touil Yasmine , Igoudjil Wassila , Corvaisier Matthieu , Dessein Anne-Frédérique , Vandomme Jérôme , Monté Didier , Stechly Laurence , Skrypek Nicolas , Langlois Carole , Grard Georges , Millet Guillaume , Leteurtre Emmanuelle , Dumont Patrick , Truant Stéphanie , Pruvot François-René , Hebbar Mohamed , Fan Fan , Ellis Lee M. , Formstecher Pierre , Van Seuningen Isabelle , Gespach Christian , Polakowska Renata , Huet Guillemette
Published: April 2023

PDF file - 309K, Figure S1. Expression of cancer stem cell phenotypes in 5FU-resistant 5F7 and 5F31 clones.
Supplemental Figure 5 from Mesenchymal Stem Cells from Human Fat Engineered to Secrete BMP4 Are Nononcogenic, Suppress Brain Cancer, and Prolong Survival
Authors: Li Qian , Wijesekera Olindi , Salas Sussan J. , Wang Joanna Y. , Zhu Mingxin , Aprhys Colette , Chaichana Kaisorn L. , Chesler David A. , Zhang Hao , Smith Christopher L. , Guerrero-Cazares Hugo , Levchenko Andre , Quinones-Hinojosa Alfredo
Published: April 2023

Supplemental SFig. 5. hAMSCs do not form tumors in vivo.
Supplementary Figure S4 from Alpha-Smooth Muscle Actin (ACTA2) Is Required for Metastatic Potential of Human Lung Adenocarcinoma
Authors: Lee Hye Won , Park Young Mi , Lee Se Jeong , Cho Hyun Jung , Kim Duk-Hwan , Lee Jung-Il , Kang Myung-Soo , Seol Ho Jun , Shim Young Mog , Nam Do-Hyun , Kim Hyeon Ho , Joo Kyeung Min
Published: April 2023

Supplementary Figure S4 - PDF file 40K, Supplementary Figure S4. ACTA2 silencing did not affect proliferation, anoikis resistance, and adhesion A, To investigate the effect of ACTA2 silencing on proliferation, stable cells were seeded into 96-well plate and cellular proliferation was checked after 72 hours using EZ-Cytox cell viability assay kit. B, Cells undergoing death by anoikis were identified and quantified using the CytoSelectTM 24-well Anoikis Assay kit (Cell Bioloabs) according to the manufacturer's instructions. Stable cells were added into either an anchorage-resistant poly-hema-coated or a control uncoated plate. After a 24 hours incubation, cell viability was determined using MTT. C, To perform cell adhesion assay, stable cells were seeded into 96-well plate precoated with 10 microg/mL ?bronectin (Millipore) and incubated for 1 hour. After 3 times washing with PBS to remove the unattached cells, the adherent cells were dyed with 0.1% crystal violet for 30 min at room temperature and solubilized with 2% sodium dodecyl sulfate (SDS). Absorbance at 550 nm was measured to determine cellular adhesion
Supplementary Methods and Legend from BRaf and MEK Inhibitors Differentially Regulate Cell Fate and Microenvironment in Human Hepatocellular Carcinoma
Authors: Breunig Christian , Mueller Bernadett J. , Umansky Ludmila , Wahl Kristin , Hoffmann Katrin , Lehner Frank , Manns Michael P. , Bantel Heike , Falk Christine S.
Published: April 2023

Supplementary Methods and Legend
Supplementary Table 2 from PI3K Pathway Activation Provides a Novel Therapeutic Target for Pediatric Ependymoma and Is an Independent Marker of Progression-Free Survival
Authors: Rogers Hazel A. , Mayne Cerys , Chapman Rebecca J. , Kilday John-Paul , Coyle Beth , Grundy Richard G.
Published: April 2023

PDF file - 35K, The table lists genes from the PI3K pathway displaying a significant difference in mRNA expression between tumors from different locations, identified using an ANOVA test. mRNA data originally published by Johnson et al. 2010 (Geo accession number GSE21687) was used for analysis.
Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Authors: Papadopoulos Kyriakos P. , Tabernero Josep , Markman Ben , Patnaik Amita , Tolcher Anthony W. , Baselga José , Shi Weiliang , Egile Coumaran , Ruiz-Soto Rodrigo , Laird A. Douglas , Miles Dale , LoRusso Patricia M.
Published: April 2023

PDF file - 1005KB, Supplementary Figure 1. Mean (+ or - SE) SAR245409 Plasma Concentration-Time Profiles on Days 1 and 27 of Cycle 1.
Supplementary Figure 6 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Authors: Valentino Joseph D. , Li Jing , Zaytseva Yekaterina Y. , Mustain W. Conan , Elliott Victoria A. , Kim Ji Tae , Harris Jennifer W. , Campbell Katherine , Weiss Heidi , Wang Chi , Song Jun , Anthony Lowell , Townsend Courtney M. , Evers B. Mark
Published: April 2023

PDF file - 1066KB, MEK inhibition alone and combination PI3K + MEK inhibition decreases serotonin secretion, while BEZ235 decreases CgA expression. (A) BON and (B) QGP-1 cells were plated in 24 well plates at a density of 1x105 cells/cm2. After 24h, cells were washed and maintained with serum-free medium. Cells were subsequently treated with either (upper panels) control, BKM120 (5 �M), PD0325901 (100 nM), or combination BKM120 + PD0325901 (5 �M/100 nM), or (lower panels) control, BEZ235 (1000 nM), PD0325901 (100 nM), or combination BEZ235 + PD0325901 (1000 nM/100 nM) for 1h. Media was collected and serotonin measured by serotonin ELISA (* p < 0.05 vs. control). (C) Whole cell lysates were collected following 24h of drug treatment with either control, BKM120 (5 �M), PD0325901 (100 nM), or combination BKM120 + PD0325901 (5 �M/100 nM), or control, BEZ235 (1000 nM), PD0325901 (100 nM), or combination BEZ235 + PD0325901 (1000 nM/100 nM) and analyzed for CgA expression. β-actin was used as a loading control.
Supplementary Figure 3 from Cotargeting the PI3K and RAS Pathways for the Treatment of Neuroendocrine Tumors
Authors: Valentino Joseph D. , Li Jing , Zaytseva Yekaterina Y. , Mustain W. Conan , Elliott Victoria A. , Kim Ji Tae , Harris Jennifer W. , Campbell Katherine , Weiss Heidi , Wang Chi , Song Jun , Anthony Lowell , Townsend Courtney M. , Evers B. Mark
Published: April 2023

PDF file - 741KB, PI3K inhibition enhances apoptosis in NCI-H727 and QGP-1 cell lines. (A) NCI-H727 and (B) QGP-1 cells were plated in 24 well plates at a density of 5x104 cells/cm2. Treatments were initiated the following morning with increasing doses of either BKM120 (0-5 μM) (upper panels) or BEZ235 (0-1000 nM) (lower panels) and continued for 24h. Apoptosis was measured by DNA fragmentation using the Cell Death Detection ELISAplus (* p < 0.05 vs. control).
Supplementary Table 2 from EZH2 Protein Expression Associates with the Early Pathogenesis, Tumor Progression, and Prognosis of Non–Small Cell Lung Carcinoma
Authors: Behrens Carmen , Solis Luisa M. , Lin Heather , Yuan Ping , Tang Ximing , Kadara Humam , Riquelme Erick , Galindo Hector , Moran Cesar A. , Kalhor Neda , Swisher Stephen G. , Simon George R. , Stewart David J. , Lee J. Jack , Wistuba Ignacio I.
Published: April 2023

PDF file 68K, C-index of Cox proportional hazard models of outcome of lung adenocarcinoma patients
Supplementary Figure Legend from Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Authors: Lian Bin , Si Lu , Cui Chuanliang , Chi Zhihong , Sheng Xinan , Mao Lili , Li Siming , Kong Yan , Tang Bixia , Guo Jun
Published: April 2023

Supplementary Figure Legend - PDF file 46K, Supplementary Figure Legends for Supplemental Figure S1
Figure S1 from Phase II Randomized Trial Comparing High-Dose IFN-α2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
Authors: Lian Bin , Si Lu , Cui Chuanliang , Chi Zhihong , Sheng Xinan , Mao Lili , Li Siming , Kong Yan , Tang Bixia , Guo Jun
Published: April 2023

Figure S1 - PDF file 4805K, Fig. S1. CONSORT trial flow diagram
Supplementary Table 1, Figures 1 - 3 from Population Pharmacokinetics of Bevacizumab in Children with Osteosarcoma: Implications for Dosing
Authors: Turner David C. , Navid Fariba , Daw Najat C. , Mao Shenghua , Wu Jianrong , Santana Victor M. , Neel Michael , Rao Bhaskar , Willert Jennifer Reikes , Loeb David M. , Harstead K. Elaine , Throm Stacy L. , Freeman Burgess B. , Stewart Clinton F.
Published: April 2023

PDF file - 200K, Supplementary Table 1. Comparison of predictive performance for model parameterizations A, (B), and C (with IBW covariate) Supplemental Figure 1. The base structural bevacizumab model consisted of a two compartment model parameterized in terms of clearance from the central compartment and intercompartmental transfer to and from central and peripheral compartments. Supplemental Figure 2. Observed concentration-time data (filled diamonds) with simulations from individual posthoc parameter estimates (dashed lines; ~2 hrs step size) indicate that bevacizumab exhibits bi-exponential decay with a relatively rapid alpha phase and a prolonged beta terminal phase. Supplemental Figure 3. Visual predictive check of observed and model-predicted serum bevacizumab concentrations following 15 mg/kg dosing over a course of three occasions. The shaded region represents the 95% confidence interval of the Monte Carlo model simulations.
Supplementary Figure 4 from The PDGFRβ–AKT Pathway Contributes to CDDP-Acquired Resistance in Testicular Germ Cell Tumors
Authors: Juliachs M. , Muñoz C. , Moutinho C.A. , Vidal A. , Condom E. , Esteller M. , Graupera M. , Casanovas O. , Germà J.R. , Villanueva A. , Viñals F.
Published: April 2023

PDF file - 364K, Figure S4 presents the results of PDGF-BB expression by RT-PCR and ELISA analysis in TGT38 and TGT38R tumors.
Supplementary Methods from Synergistic Antitumor Activity of Cetuximab and Namitecan in Human Squamous Cell Carcinoma Models Relies on Cooperative Inhibition of EGFR Expression and Depends on High EGFR Gene Copy Number
Authors: De Cesare Michelandrea , Lauricella Calogero , Veronese Silvio Marco , Cominetti Denis , Pisano Claudio , Zunino Franco , Zaffaroni Nadia , Zuco Valentina
Published: April 2023

PDF file - 107K
Supplementary Figure Legend from Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma
Authors: Leshchenko Violetta V. , Kuo Pei-Yu , Jiang Zewei , Thirukonda Venu K. , Parekh Samir
Published: April 2023

PDF file - 66K
Supplementary Figure 3 from Integrative Genomic Analysis of Temozolomide Resistance in Diffuse Large B-Cell Lymphoma
Authors: Leshchenko Violetta V. , Kuo Pei-Yu , Jiang Zewei , Thirukonda Venu K. , Parekh Samir
Published: April 2023

PDF file - 625K, DAC induces expression of aberrantly methylated and expressed genes in TMZ resistant DLBCL.
Supplementary Figure 3 from Measles Virus Vaccine–Infected Tumor Cells Induce Tumor Antigen Cross-Presentation by Human Plasmacytoid Dendritic Cells
Authors: Guillerme Jean-Baptiste , Boisgerault Nicolas , Roulois David , Ménager Jérémie , Combredet Chantal , Tangy Frédéric , Fonteneau Jean-François , Gregoire Marc
Published: April 2023

PDF file - 115K, Supplemental figure 3: Infection of pDC by MV-eGFP or UV-irradiated MV-eGFP: pDC in presence of IL-3 or Meso13 cells were cultured alone (NI) or with MV-eGFP (MV) or UV-irradiated (312nm - 100kj/m�) MV-eGFP (MV*) at MOI=50 during 72hrs (upper panel) or during 2hrs and then cultured during 70hrs (lower panel). Fluorescence was analyzed by flow cytometry.
Supplementary Legend from Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Authors: Allard Bertrand , Pommey Sandra , Smyth Mark J. , Stagg John
Published: April 2023

Supplementary Legend - PDF file 89K, Supplementary legend
Supplementary Fig S1 from Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
Authors: Allard Bertrand , Pommey Sandra , Smyth Mark J. , Stagg John
Published: April 2023

Supplementary Fig S1 - PDF file 103K, Figure S1. Anti-CD73 mAb enhances the activity of anti-PD-1 and anti-CTLA-4 mAbs against RM-1 tumors
Supplementary Table 2 from Serum Antibodies to Blood Group A Predict Survival on PROSTVAC-VF
Authors: Campbell Christopher T. , Gulley James L. , Oyelaran Oyindasola , Hodge James W. , Schlom Jeffrey , Gildersleeve Jeffrey C.
Published: April 2023

PDF file - 112K, Summary of survival correlations for pre-vaccination antibody levels
Supplementary Table 2 from Sequential Binary Gene Ratio Tests Define a Novel Molecular Diagnostic Strategy for Malignant Pleural Mesothelioma
Authors: De Rienzo Assunta , Richards William G. , Yeap Beow Y. , Coleman Melissa H. , Sugarbaker Peter E. , Chirieac Lucian R. , Wang Yaoyu E. , Quackenbush John , Jensen Roderick V. , Bueno Raphael
Published: April 2023

XLSX file - 191K, Results of the binary diagnostic tests using microarray data and RT-PCR data in the original set of samples.
Supplementary Figure 5 from PID1 (NYGGF4), a New Growth-Inhibitory Gene in Embryonal Brain Tumors and Gliomas
Authors: Erdreich-Epstein Anat , Robison Nathan , Ren Xiuhai , Zhou Hong , Xu Jingying , Davidson Tom B. , Schur Mathew , Gilles Floyd H. , Ji Lingyun , Malvar Jemily , Shackleford Gregory M. , Margol Ashley S. , Krieger Mark D. , Judkins Alexander R. , Jones David T.W. , Pfister Stefan M. , Kool Marcel , Sposto Richard , Asgharazadeh Shahab
Published: April 2023

PDF file 92K, Supplemental Fig 5: Expression of PID1 protein in human brain tumors and cell lines
Supplementary Figure Legends from Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
Authors: McCaffery Ian , Tudor Yanyan , Deng Hongjie , Tang Rui , Suzuki Samuel , Badola Sunita , Kindler Hedy L. , Fuchs Charles S. , Loh Elwyn , Patterson Scott D. , Chen Li , Gansert Jennifer L.
Published: April 2023

PDF - 43K
Supplementary Figure 7 from Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma
Authors: Zheng Ying , McFarland Braden C. , Drygin Denis , Yu Hao , Bellis Susan L. , Kim Hyunsoo , Bredel Markus , Benveniste Etty N.
Published: April 2023

PDF file - 55K, Supplemental Figure 7. CX-4945 Abrogates GBM Cell Survival.
Supplementary Figure 3 from Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma
Authors: Zheng Ying , McFarland Braden C. , Drygin Denis , Yu Hao , Bellis Susan L. , Kim Hyunsoo , Bredel Markus , Benveniste Etty N.
Published: April 2023

PDF file - 67K, Supplemental Figure 3. Inhibition of CK2 Suppresses Constitutive AKT Activation in GBM Cells.
Supplementary Figure 1 from Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells
Authors: Cosimo Emilio , McCaig Alison M. , Carter-Brzezinski Luke J.M. , Wheadon Helen , Leach Michael T. , Le Ster Karine , Berthou Christian , Durieu Emilie , Oumata Nassima , Galons Hervé , Meijer Laurent , Michie Alison M.
Published: April 2023

PDF file - 56K, Chemical structures of purine analogues of roscovitine used in this study.
Supplementary Figure Legend from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair
Authors: Wei Dongping , Parsels Leslie A. , Karnak David , Davis Mary A. , Parsels Joshua D. , Marsh Amanda C. , Zhao Lili , Maybaum Jonathan , Lawrence Theodore S. , Sun Yi , Morgan Meredith A.
Published: April 2023

PDF file - 78K
Supplementary Figure 8 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair
Authors: Wei Dongping , Parsels Leslie A. , Karnak David , Davis Mary A. , Parsels Joshua D. , Marsh Amanda C. , Zhao Lili , Maybaum Jonathan , Lawrence Theodore S. , Sun Yi , Morgan Meredith A.
Published: April 2023

PDF file - 65K, LB100 plus radiation produces minimal weight loss.
Supplementary Figure 1 from Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair
Authors: Wei Dongping , Parsels Leslie A. , Karnak David , Davis Mary A. , Parsels Joshua D. , Marsh Amanda C. , Zhao Lili , Maybaum Jonathan , Lawrence Theodore S. , Sun Yi , Morgan Meredith A.
Published: April 2023

PDF file - 71K, Identification of PPP2R1A as a sensitizing target through an siRNA library screen.
Supplementary Figures 1-3 from Urinary TMPRSS2:ERG and PCA3 in an Active Surveillance Cohort: Results from a Baseline Analysis in the Canary Prostate Active Surveillance Study
Authors: Lin Daniel W. , Newcomb Lisa F. , Brown Elissa C. , Brooks James D. , Carroll Peter R. , Feng Ziding , Gleave Martin E. , Lance Raymond S. , Sanda Martin G. , Thompson Ian M. , Wei John T. , Nelson Peter S.
Published: April 2023

PDF - 160K, Supplementary Figure S1. ROC analysis of serum PSA, TMPRSS2:ERG, PCA3, alone and in combination, for prediction of ��34% positive biopsy cores at time of specimen collection. AUC(PSA) does not differ significantly from AUC(TMPRSS2:ERG) P = 0.31, AUC(PCA3) P = 0.21, AUC(TMPRSS2:ERG +PCA3) P = 0.21, or AUC(TMPRSS2:ERG +PCA3+PSA) P = 0.24. Supplementary Figure S2. Multivariable logistic regression analysis for the prediction of high Gleason grade (��7) at time of specimen collection. (A) ROC curve and (B) Odds ratios for each covariate. N = 360 Supplementary Figure S3. Multivariable logistic regression analysis for the prediction of high Gleason grade (��7) at time of specimen collection. Participants with an abnormal DRE were excluded. (A) ROC curve and (B) Odds ratios for each covariate. N = 308.
Supplementary Tables 1 - 8, Figures 1 - 7 from Discrete Molecular Classes of Ovarian Cancer Suggestive of Unique Mechanisms of Transformation and Metastases
Authors: Gardi Nilesh L. , Deshpande Tejaswini U. , Kamble Swapnil C. , Budhe Sagar R. , Bapat Sharmila A.
Published: April 2023

PDF file - 2135K, Supplementary Table 1. List of TCGA samples used in analyses. Supplementary Figure S1. Identification of EMT target genes. Supplementary Table 2. List of EMT-TF targets and LPA-S1P signaling components. Supplementary Figure S2. Tumor classification by M-classification approach Supplementary Figure S3. Derivation of the 39 metastases-associated gene. Set Supplementary Table 3. Literature based functional assignment of the 39 gene set with metastases Supplementary Data1. Weighted gene co-expression network analysis (WGCNA) and module identification (W-classification). Supplementary Data 2. Classification and module gene validation in additional Ovarian Cancer datasets (VDs). Supplementary Data 3. Identification of class-defining features using Gene Set Enrichment Analysis (GSEA). Supplementary Table 4: Modules and associated Genes. Supplementary Table 5: Class Functionalities based on Enriched Module Genes. Supplementary Table 6. Ovarian cancer cell line datasets. Supplementary Fig. S4. Representative Wound Healing Assay Images. Supplementary Fig. S5. Graphical representation of wound healing. Supplementary Figure S6. Representative immunofluorescence image of Class2 invasion. Supplementary Figure S7. Representative Immunofluorescence expression images of markers. Supplementary Table 7. Correlation between TCGA subtypes and MW classes. Supplementary Table 8. Correlation between MW classes and iE-iM subtypes.